Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $480.6 million.

  • Apellis Pharmaceuticals' Cash & Current Investments rose 2068.94% to $480.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $480.6 million, marking a year-over-year increase of 2068.94%. This contributed to the annual value of $412.6 million for FY2024, which is 1711.98% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Cash & Current Investments stood at $480.6 million for Q3 2025, which was up 2068.94% from $371.5 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Cash & Current Investments' 5-year high stood at $965.3 million during Q1 2022, with a 5-year trough of $327.0 million in Q1 2024.
  • Its 5-year average for Cash & Current Investments is $549.2 million, with a median of $480.6 million in 2025.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Cash & Current Investments surged by 6466.07% in 2022, and later crashed by 5732.73% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Cash & Current Investments (Quarter) stood at $700.6 million in 2021, then dropped by 21.05% to $553.1 million in 2022, then crashed by 36.3% to $352.3 million in 2023, then grew by 17.12% to $412.6 million in 2024, then rose by 16.48% to $480.6 million in 2025.
  • Its last three reported values are $480.6 million in Q3 2025, $371.5 million for Q2 2025, and $359.8 million during Q1 2025.